ADMA Biologics develops and commercializes plasma-derived biologics, notably intravenous immunoglobulin (IVIG) therapies for patients with primary immunodeficiency and related immune conditions. The company operates plasma collection centers and manufacturing capacity to control more of the supply chain from donor plasma to finished product. Its franchise targets specialty immunology markets where product purity, supply reliability, and labeled indications matter to physicians and payers.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 122 | — | 34.2 | 13.6% |
| Q3 2025 | 134.2 | — | 36.4 | 4.2% |
| Q4 2025 | 139.2 | — | 49.4 | 49.2% |
| Q1 2026 | 114.5 | — | 45.3 | 73.4% |
| Q2 2026 | 124.4 | 2% | 37.8 | 10.5% |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Zymeworks Inc. (ZYME), Perdoceo Education Corporation (PRDO), Allegiant Travel Company (ALGT), Polibeli Group Ltd (PLBL), Establishment Labs Holdings Inc. (ESTA), Nanobiotix S.A. (NBTX)